TBX20

Across TCGA pan-cancer cohorts, TBX20 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of TBX20’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TBX20 RNA is repressed in tumor relative to normal tissue. In most cancer types TBX20 is over-expressed in tumor, although a few such as BLCA and LIHC show the opposite, repressed pattern.

BLCA, UCEC, and COAD are the cancer types where TBX20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBX20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−2.425	.001	8	view →
UCEC	All	All	+0.565	.001	6	view →
COAD	All	All	+0.463	<.001	6	view →
BRCA	All	II,III,IV	+0.413	<.001	6	view →
LUSC	All	All	+0.398	<.001	4	view →
KIRP	All	All	+0.345	.028	3	view →
HNSC	Male	All	+0.263	.016	3	view →
LIHC	Male	All	−0.194	<.001	3	view →
READ	All	All	+0.889	.006	2	view →
LUAD	All	All	+0.177	.007	2	view →
THCA	Female	All	−0.021	.002	2	view →
STAD	Male	IV	−0.065	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

TBX20–BLCA

Open the BLCA breakdown →